Ovid Therapeutics (OVID) Set to Release Earnings on Wednesday

Ovid Therapeutics (NASDAQ:OVID) is expected to be posting its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $0.03 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Ovid Therapeutics (NASDAQ:OVID) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.04. The company had revenue of $0.73 million during the quarter, compared to the consensus estimate of $0.02 million. On average, analysts expect Ovid Therapeutics to post ($0.37) EPS for the current fiscal year and ($0.38) EPS for the next fiscal year.

Ovid Therapeutics Trading Up 0.8%

Shares of OVID stock opened at $2.41 on Wednesday. Ovid Therapeutics has a 12-month low of $1.18 and a 12-month high of $3.11. The company has a debt-to-equity ratio of 0.05, a current ratio of 12.39 and a quick ratio of 12.39. The firm has a fifty day moving average of $2.52 and a 200-day moving average of $2.36.

Analyst Ratings Changes

Several analysts have issued reports on OVID shares. HC Wainwright lifted their price target on Ovid Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research note on Friday, September 11th. Wall Street Zen upgraded Ovid Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Roth Capital reiterated a “buy” rating and set a $8.00 price objective on shares of Ovid Therapeutics in a report on Thursday, September 3rd. B. Riley Financial reissued a “buy” rating on shares of Ovid Therapeutics in a research report on Tuesday, July 21st. Finally, Wolfe Research began coverage on Ovid Therapeutics in a research note on Thursday, October 15th. They issued an “outperform” rating and a $5.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Ovid Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $6.00.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines for epilepsies and other disorders of the central nervous system. The company’s research has concentrated on conditions with significant unmet medical needs, including rare epileptic and neurodevelopmental disorders.

Ovid’s pipeline has included soticlestat, an investigational therapy developed in collaboration with Takeda Pharmaceutical Company for developmental and epileptic encephalopathies such as Dravet syndrome and Lennox-Gastaut syndrome.